Emcure unit acquires Mantra Pharma shares for CAD 50 million
Marcan Pharmaceuticals Inc., a wholly-owned subsidiary of Emcure Pharmaceuticals, acquired 100% of the Class E Special Shares in its step-down subsidiary Mantra Pharma Inc. for CAD 50 million on July 02, 2026. The transaction, finalized on July 03, 2026, was undertaken at arm's length and is exempt from related party transaction regulations under SEBI LODR. Mantra Pharma, incorporated in Quebec, Canada, reported a turnover of CAD 96.67 million for FY26.
*this image is generated using AI for illustrative purposes only.
Marcan Pharmaceuticals Inc., a subsidiary of Emcure Pharmaceuticals , has acquired 100% of the Class E Special Shares in its step-down subsidiary Mantra Pharma Inc. for an aggregate cash consideration of CAD 50 million. The acquisition, executed through share purchase agreements on July 02, 2026, ensures that Mantra continues to be a wholly-owned subsidiary of Marcan. This strategic move consolidates control over the Canadian entity, which reported an annual turnover of CAD 96.67 million for the financial year 2026. The acquisition was finalized on July 03, 2026.
Transaction Structure and Regulatory Compliance
The transaction constitutes a related party transaction between two wholly-owned subsidiaries but is exempt under Regulation 23(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The deal was undertaken at arm's length, and no specific government approvals were required beyond the completion of requisite compliances under applicable laws in Canada.
About Mantra Pharma Inc.
Mantra Pharma Inc. is incorporated under the laws of Quebec, Canada, and is engaged in the marketing and distribution of prescription drugs and natural health products. The entity was formed on November 06, 2023, through an amalgamation of several companies. Its capital structure consists of 1,000 Class A Common Shares and 24,000,000 Class E Special Shares without par value.
Key Deal Parameters
The following table summarises the key details of the acquisition:
| Parameter: | Details |
|---|---|
| Acquirer: | Marcan Pharmaceuticals Inc. |
| Target: | Mantra Pharma Inc. |
| Consideration: | CAD 50 million |
| Stake Acquired: | 100% Class E Special Shares |
| Agreement Date: | July 02, 2026 |
| Completion Date: | July 03, 2026 |
| Incorporation: | Quebec, Canada |
Financial Performance of Mantra Pharma Inc.
The financial performance of Mantra has shown significant growth over the last three financial years. The aggregate historical turnover for the period ending March 31, 2026, reflects a steady increase in business operations within the Canadian market.
| Financial Year: | Turnover (CAD) |
|---|---|
| 2026 | 96.67 million |
| 2025 | 81.01 million |
| 2024* | 28.26 million |
*For the period November 06, 2023 till March 31, 2024.
Historical Stock Returns for Emcure Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.82% | +4.66% | +4.62% | +20.23% | +31.42% | +37.86% |
How will the CAD 50 million cash outflow impact Marcan Pharmaceuticals' liquidity and capital allocation plans for the remainder of the fiscal year?
What specific synergies or operational efficiencies does Emcure Pharmaceuticals expect to achieve by fully consolidating Mantra Pharma?
Given Mantra's rapid revenue growth, what are the projected revenue and profit margins for the Canadian subsidiary post-acquisition?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
